X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4971) 4971
Dissertation (87) 87
Newspaper Article (55) 55
Book Chapter (46) 46
Publication (17) 17
Book / eBook (7) 7
Conference Proceeding (7) 7
Government Document (3) 3
Book Review (2) 2
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2418) 2418
alk (2331) 2331
oncology (1746) 1746
female (1108) 1108
crizotinib (1080) 1080
anaplastic lymphoma kinase (1056) 1056
male (1050) 1050
cancer (872) 872
lung cancer (838) 838
mutation (806) 806
middle aged (772) 772
lung neoplasms - genetics (734) 734
adult (717) 717
immunohistochemistry (692) 692
chemotherapy (689) 689
pathology (682) 682
lymphomas (673) 673
receptor protein-tyrosine kinases - genetics (647) 647
aged (581) 581
animals (562) 562
egfr (561) 561
expression (547) 547
identification (543) 543
tumors (539) 539
gene (514) 514
lung neoplasms - drug therapy (513) 513
adenocarcinoma (512) 512
hemic and lymphatic diseases (502) 502
carcinoma, non-small-cell lung - genetics (501) 501
lung neoplasms - pathology (501) 501
lung cancer, non-small cell (453) 453
carcinoma, non-small-cell lung - drug therapy (435) 435
non-small cell lung cancer (435) 435
kinases (424) 424
respiratory system (412) 412
gene rearrangement (408) 408
mutations (393) 393
cell lung-cancer (386) 386
genetic aspects (384) 384
prognosis (376) 376
receptor protein-tyrosine kinases - metabolism (368) 368
open-label (367) 367
nsclc (360) 360
analysis (339) 339
cell biology (339) 339
protein kinase inhibitors - therapeutic use (335) 335
lymphoma (334) 334
resistance (330) 330
cell line, tumor (327) 327
neuroblastoma (325) 325
protein-tyrosine kinases - genetics (325) 325
carcinoma, non-small-cell lung - pathology (317) 317
hematology (311) 311
oncogene proteins, fusion - genetics (311) 311
research (311) 311
aged, 80 and over (309) 309
metastasis (296) 296
in situ hybridization, fluorescence (291) 291
receptor protein-tyrosine kinases (289) 289
proteins (288) 288
antineoplastic agents - therapeutic use (287) 287
care and treatment (281) 281
mice (280) 280
fusion (279) 279
ros1 (279) 279
eml4-alk fusion gene (278) 278
npm-alk (278) 278
patients (273) 273
receptor protein-tyrosine kinases - antagonists & inhibitors (271) 271
biochemistry & molecular biology (269) 269
child (269) 269
anaplastic large cell lymphoma (266) 266
protein-tyrosine kinase (264) 264
adenocarcinoma - genetics (259) 259
alectinib (259) 259
protein kinase inhibitors - pharmacology (255) 255
pharmacology & pharmacy (251) 251
protein-tyrosine kinases - metabolism (244) 244
receptor tyrosine kinase (244) 244
adolescent (243) 243
genes (243) 243
tyrosine (237) 237
ceritinib (234) 234
diagnosis (233) 233
kinase (231) 231
inflammatory myofibroblastic tumor (225) 225
activating mutations (223) 223
acquired-resistance (219) 219
tyrosine kinase (218) 218
non-hodgkins-lymphoma (216) 216
non-small cell lung carcinoma (215) 215
cancer therapies (206) 206
health aspects (206) 206
alk rearrangement (202) 202
review (202) 202
gefitinib (201) 201
targeted therapy (200) 200
treatment outcome (197) 197
inhibitor (196) 196
lymphoma, large-cell, anaplastic - pathology (196) 196
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (6) 6
Trinity College (John W Graham) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Online Resources - Online (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4659) 4659
German (277) 277
Chinese (153) 153
French (75) 75
Japanese (45) 45
Russian (17) 17
Korean (14) 14
Spanish (10) 10
Portuguese (7) 7
Italian (6) 6
Czech (4) 4
Polish (4) 4
Norwegian (2) 2
Slovak (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
Persian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic advances in medical oncology, ISSN 1758-8359, 2018, Volume 10, p. 175883591878936
Anaplastic lymphoma kinase (ALK) rearrangement is identified in 3–7% of advanced non-small cell lung cancer (NSCLC) cases, and ALK tyrosine kinase inhibitors... 
ALK | non-small cell lung cancer | ALK–TKI | NSCLC | ALK-rearranged NSCLC | ALK–tyrosine kinase inhibitors | ALK inhibitors | EML4–ALK | alectinib | alectinib clinical trials | FUSION | TYROSINE KINASE | OPEN-LABEL | PHASE-2 | SINGLE-ARM | ALK-tyrosine kinase inhibitors | EML4-ALK | GENE | ONCOLOGY | CRIZOTINIB | RESISTANCE | INHIBITORS | ALK-TKI
Journal Article
Biochemical journal, ISSN 1470-8728, 2009, Volume 420, Issue 3, pp. 345 - 361
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and differentiation. In addition, RTKs reveal oncogenic potential when their... 
Extracellular-signal-regulated kinase (ERK) | Pleiotrophin | Anaplastic large cell lymphoma (ALCL) | Neuroblastoma | Non-small cell lung cancer (NSLCL) | Midkine | Anaplastic lymphoma kinase (ALK) | Inflammatory myofibroblastic tumour (IMT) | ALK PROTEIN EXPRESSION | inflammatory myofibroblastic tumour (IMT) | NPM-ALK | HEPARIN-BINDING | GROWTH-FACTOR PLEIOTROPHIN | non-small cell lung cancer (NSLCL) | BIOCHEMISTRY & MOLECULAR BIOLOGY | anaplastic lymphoma kinase (ALK) | EML4-ALK FUSION GENE | neuroblastoma | LARGE-CELL LYMPHOMA | extracellular-signal-regulated kinase (ERK) | pleiotrophin | NEUROTROPHIC FACTOR HBNF | INFLAMMATORY MYOFIBROBLASTIC TUMOR | NON-HODGKINS-LYMPHOMA | midkine | anaplastic large cell lymphoma (ALCL) | RECEPTOR TYROSINE KINASE | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Oncogene Proteins, Fusion - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Neuroblastoma - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung Neoplasms - pathology | Nuclear Proteins - metabolism | Receptor Protein-Tyrosine Kinases | Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Neuroblastoma - metabolism | Nuclear Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - metabolism | Neuroblastoma - pathology | Lymphoma, Large-Cell, Anaplastic - genetics | ALK, anaplastic lymphoma kinase | LTK, leucocyte tyrosine kinase | MUC-1, mucin-1 | IRS-1, IR substrate-1 | PTN, pleiotrophin | TGFβ, transforming growth factor β | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | Shc, Src homology and collagen homology | TPM, tropomyosin | IMP cyclohydrolase | MK, midkine | MYH9, non-muscle myosin heavy chain | MAM, meprin, A5 protein and receptor protein tyrosine phosphatase mu | NPM, nucleophosmin | mTOR, mammalian target of rapamycin | NIPA, nuclear interacting partner of ALK | RPTP, receptor protein tyrosine phosphatase | DLBCL, diffuse large B-cell lymphoma | FOXO3a, forkhead box O 3a | NF-κB, nuclear factor κB | Shp1, SH2 domain-containing phosphatase 1 | RANBP2, Ran-binding protein 2 | ALCL, anaplastic large cell lymphoma | Dpp, decapentaplegic | FRS2, fibroblast growth factor receptor substrate 2 | LDLa, low-density lipoprotein class A | EGFR, epidermal growth factor receptor | SEC31L1, SEC31 homologue A | GIST, gastrointestinal stromal tumour | RTK, receptor tyrosine kinase | SH2, Src homology 2 | TFG, TRK-fused gene | ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | CLTC, clathrin heavy chain | MAPK, mitogen-activated protein kinase | Hen-1, hesitation-1 | MEK, MAPK | PI3K, phosphoinositide 3-kinase | HEK, human embryonic kidney | SCD-2, suppressor of constitutive dauer 2 | Review | EBPβ, CCAAT | CARS, cysteinyl-tRNA synthetase | JNK, c-Jun N-terminal kinase | ERK kinase | Grb2, growthfactor-receptor-bound protein 2 | SCC, squamous cell carcinoma | EML4, echinoderm microtubule-associated protein like 4 | SHH, sonic hedghog | BCR-Abl, breakpoint cluster region-Abl | IR, insulin receptor | ALO17, ALK lymphoma oligomerization partner on chromosome 17 | enhancer-binding protein β | PLCγ, phospholipase Cγ | NSCLC, non-small cell lung cancer | UCN-01, unco-ordinated 1 | Cdc42, cell division cycle 42 | STAT, signal transducer and activator of transcription | DRG, dorsal root ganglia | MSN, moesin | dALK, Drosophila ALK | IL-3, interleukin-3 | CNS, central nervous system | JAK, Janus kinase | CML, chronic myeloid leukaemia | Jeb, jelly belly | IMT, inflammatory myofibroblastic tumour
Journal Article
Thoracic cancer, ISSN 1759-7706, 2018, Volume 9, Issue 4, pp. 423 - 430
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression... 
non‐small‐cell lung cancer (NSCLC) | ALK‐rearrangement (ALK‐R) | detection platforms | ALK‐tyrosine kinase inhibitor (TKI) | anaplastic lymphoma kinase (ALK) | ALK-rearrangement (ALK-R) | non-small-cell lung cancer (NSCLC) | ALK-tyrosine kinase inhibitor (TKI) | MOLECULAR CHARACTERIZATION | EML4-ALK FUSION GENE | OPEN-LABEL | EGFR MUTATIONS | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | RESPIRATORY SYSTEM | CRIZOTINIB | RESISTANCE | GENOMIC ALTERATIONS | INHIBITORS | RECEPTOR TYROSINE KINASE | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib - therapeutic use | Microtubule-Associated Proteins - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Proto-Oncogene Proteins - genetics | Anaplastic Lymphoma Kinase - genetics | Nuclear Pore Complex Proteins - genetics | Drug Resistance, Neoplasm - genetics | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Kinesin - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Tyrosine | Lung cancer, Non-small cell | Lymphomas | Lung cancer | Breast cancer | FDA approval | Kinases | Drug resistance | Cancer therapies | Cell adhesion & migration | Esophagus | Proteins | Chemotherapy | Mutation | Tumors | Invited Review
Journal Article
Cancer biology & therapy, ISSN 1555-8576, 2018, Volume 19, Issue 11, pp. 962 - 966
The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than... 
fusion partner gene | crizotinib | CMTR1 | ALK-tyrosine kinase inhibitor (TKI) | ALK-rearranged NSCLC | Anaplastic lymphoma kinase (ALK) | VARIANT | CHEMOTHERAPY | LUNG-CANCER | GENE | ONCOLOGY | KIF5B-ALK | CANCER STATISTICS
Journal Article
PloS one, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0120320
Background Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, and its molecular pathogenesis still remains to be elucidated. This... 
ALK GENE | SURVIVAL | FREQUENT | AMPLIFICATION | MULTIDISCIPLINARY SCIENCES | RHABDOMYOSARCOMA | RHOC GTPASE | IDENTIFICATION | ABERRATIONS | AMERICAN-SOCIETY | PATHOLOGISTS GUIDELINE RECOMMENDATIONS | Prognosis | Inflammatory Breast Neoplasms - epidemiology | Humans | Middle Aged | Proportional Hazards Models | Gene Dosage | Inflammatory Breast Neoplasms - genetics | Inflammatory Breast Neoplasms - diagnosis | Gene Amplification | Triple Negative Breast Neoplasms - genetics | Anaplastic Lymphoma Kinase | Receptor Protein-Tyrosine Kinases - genetics | Triple Negative Breast Neoplasms - diagnosis | Survival Analysis | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Aged | Retrospective Studies | Republic of Korea - epidemiology | Breast - pathology | Triple Negative Breast Neoplasms - epidemiology | Analysis | Genes | Fluorescence | Medical records | Breast cancer | Genetic aspects | Non-Hodgkin's lymphomas | Formaldehyde | Prevalence studies (Epidemiology) | Cancer | Copy number | Pathogenesis | Lung cancer | ALK protein | Oncology | Metastasis | Neuroblastoma | Paraffin | Kinases | Cancer therapies | Surgery | Fluorescence in situ hybridization | Protein-tyrosine kinase | Internal medicine | Inflammation | Regression analysis | Patients | Survival | ErbB-2 protein | Lymphoma | Molecular chains | Medicine | Gene amplification | Chemotherapy | Hospitals | Medical prognosis | Gene rearrangement | Lymphomas | Mutation | Tumors
Journal Article
Journal Article
Journal Article
Frontiers in oncology, 2014, Volume 4, pp. 1 - 26
Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy and radiotherapy, the 5-year survival... 
ALK | Lung Adenocarcinoma | ROS-1 | Met | biomarkers | EGFR
Journal Article
Oncotarget, ISSN 1949-2553, 08/2019, Volume 10, Issue 48, pp. 4937 - 4950
The gene is a major oncogene of neuroblastoma cases exhibiting ALK activating mutations. Here, we characterized two neuroblastoma cell lines established from a... 
Journal Article